Tumour size predicts risk of recurrence in tall cell subtype papillary thyroid carcinoma

被引:1
作者
Leong, David [1 ,2 ]
Leslie, Connull [3 ]
Laurie, Brodie [1 ]
Hou, Lachlan [1 ]
Keyser, Jo [4 ]
Yew, Ming Khoon [5 ,6 ]
Ryan, Simon [1 ]
Nguyen, Hieu [1 ]
Lisewski, Dean [7 ]
机构
[1] Sir Charles Gairdner Hosp, Endocrine Surg Serv Unit, Hosp Ave, Nedlands, WA 6009, Australia
[2] Univ Western Australia, Sch Surg, Nedlands, Australia
[3] QEII Med Ctr, PathWest Lab Med, Nedlands, Australia
[4] North Metropolitan Hlth Serv, Western Australia Canc Network, Nedlands, Australia
[5] Royal Perth Hosp, Dept Endocrine Surg, Perth, Australia
[6] Curtin Univ, Sch Surg, Bentley, Australia
[7] Fiona Stanley Hosp, Dept Endocrine Surg, Murdoch, Australia
关键词
Papillary thyroid carcinoma; Recurrence; Prognosis; Tall cell; AGGRESSIVE VARIANTS; CANCER;
D O I
10.1016/j.amjsurg.2024.03.022
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The tall cell subtype of papillary thyroid cancer (TCPTC) is the most common aggressive subtype and often treated aggressively. This approach may not be necessary in smaller tumours without adverse histological characteristics. Methods: 97 patients with TCPTC defined as a height-to-width ratio of >= 3:1 and at least 30% tall cells were compared against 390 classical papillary thyroid carcinoma (CPTC) based on tumour size with recurrence free survival (RFS) as the primary outcome. Results: TCPTC are more likely to present with adverse histological characteristics. In smaller tumours (<2 cm), only central lymph node metastasis (HR7.16 p = 0.03) and multifocality (HR10.11 p = 0.026) increased recurrence risk. In larger tumours, TCPTC histology (HR3.78 p = 0.002), lymphovascular invasion (HR3.02 p = 0.014) and central lymph node metastasis (HR3.24 p < 0.001) significantly increased recurrence risk. Conclusion: TCPTC tumours <2 cm without central lymph node metastasis and multifocality are similar in risk of recurrence to classical PTC and could be managed with lobectomy.
引用
收藏
页码:58 / 61
页数:4
相关论文
共 18 条
  • [1] Overview of the 2022 WHO Classification of Thyroid Neoplasms
    Baloch, Zubair W.
    Asa, Sylvia L.
    Barletta, Justine A.
    Ghossein, Ronald A.
    Juhlin, C. Christofer
    Jung, Chan Kwon
    LiVolsi, Virginia A.
    Papotti, Mauro G.
    Sobrinho-Simoes, Manuel
    Tallini, Giovanni
    Mete, Ozgur
    [J]. ENDOCRINE PATHOLOGY, 2022, 33 (01) : 27 - 63
  • [2] Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease
    Bongers, Pim J.
    Kluijfhout, Wouter P.
    Verzijl, Raoul
    Lustgarten, Mattan
    Vermeer, Marloes
    Goldstein, David P.
    Devon, Karen
    Rotstein, Lorne E.
    Asa, Sylvia L.
    Brierley, James D.
    Tsang, Richard W.
    Ezzat, Shereen
    Vriens, Menno R.
    Mete, Ozgur
    Pasternak, Jesse D.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (08) : 2533 - 2539
  • [3] Increasing incidence of thyroid cancer in the United States, 1973-2002
    Davies, L
    Welch, HG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18): : 2164 - 2167
  • [4] Elboga U, 2015, EUR REV MED PHARMACO, V19, P396
  • [5] Prognostic Implications of Papillary Thyroid Carcinoma with Tall-Cell Features
    Ganly, Ian
    Ibrahimpasic, Tihana
    Rivera, Michael
    Nixon, Ian
    Palmer, Frank
    Patel, Snehal G.
    Tuttle, R. Michael
    Shah, Jatin P.
    Ghossein, Ronald
    [J]. THYROID, 2014, 24 (04) : 662 - 670
  • [6] 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
    Haugen, Bryan R.
    Alexander, Erik K.
    Bible, Keith C.
    Doherty, Gerard M.
    Mandel, Susan J.
    Nikiforov, Yuri E.
    Pacini, Furio
    Randolph, Gregory W.
    Sawka, Anna M.
    Schlumberger, Martin
    Schuff, Kathryn G.
    Sherman, Steven I.
    Sosa, Julie Ann
    Steward, David L.
    Tuttle, R. Michael
    Wartofsky, Leonard
    [J]. THYROID, 2016, 26 (01) : 1 - 133
  • [7] Prognostic Outcomes of Tall Cell Variant Papillary Thyroid Cancer: A Meta-Analysis
    Jalisi, Scharukh
    Ainsworth, Tiffiny
    LaValley, Michael
    [J]. JOURNAL OF THYROID RESEARCH, 2010, 2010
  • [8] Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients
    Kazaure, Hadiza S.
    Roman, Sanziana A.
    Sosa, Julie A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (06) : 1874 - 1880
  • [9] Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant
    Kim, Kwangsoon
    Jung, Chan Kwon
    Lim, Dong-Jun
    Bae, Ja Seong
    Kim, Jeong Soo
    [J]. GLAND SURGERY, 2022, 11 (01) : 56 - 66
  • [10] A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis
    Liu, Zeming
    Zeng, Wen
    Chen, Tianwen
    Guo, Yawen
    Zhang, Chao
    Liu, Chunping
    Huang, Tao
    [J]. ONCOTARGET, 2017, 8 (04) : 6222 - 6232